
Opinion|Videos|November 27, 2024
Managing Treatment Challenges in HER2-Directed Therapies
Key Takeaways
- Understanding molecular mechanisms of resistance is crucial for developing novel therapeutic agents and combination strategies in HER2-directed therapies.
- Personalized medicine, utilizing genomic profiling, is expected to tailor treatments to individual patient profiles, enhancing efficacy.
An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
Health Equity & Access Weekly Roundup: November 20, 2026
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5


